UNSPSC 51142043: Propacetamol hydrochloride

This classification denotes an analgesic and antipyretic with the molecular formula C14H20N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH41QYH8E5, chemically known as 4-acetamidophenyl n,n-diethylaminoacetate monohydrochloride but more generally known as propacetamol hydrochloride, which bears US NIH Compound Identifier 108082. European Medicines Agency schedules Propacetamol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04076MIG.

Most nations, for tariff and trade purposes, schedule propacetamol hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, PROPACETAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CC(=O)OC1CCC(CC1)NC(=O)C.CL.

UNSPSC 51142043 Propacetamol hydrochloride is a Commodity code that in practice spans a broader pharmaceutical and OTC product procurement landscape than the narrow code name suggests. State and local governments soliciting under this code are acquiring naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and OTC products to support community health, emergency response, and healthcare delivery missions. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work ranges from direct purchases of emergency-response medications and health supplies to participation in master-contract frameworks managed by cooperative purchasing organizations that distribute products through authorized pharmaceutical wholesalers to participating state agencies, counties, and localities.

Recent activity shows Seminole County, Florida (IFB 60459723LAS, due July 26, 2026) procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission (RFI HHS0017013, due April 3, 2026) is gathering market intelligence on direct-to-manufacturer prescription programs to support its Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) is establishing multi-award contracts for generic pharmaceuticals and OTC products to serve participating state and local government facilities across Minnesota and Oregon, requiring submission of detailed product information including National Drug Codes, with contract effectiveness on July 1, 2026. Geographic activity centers on Florida, Texas, and Minnesota, with secondary reach across participating states in cooperative purchasing networks. Vendors must typically meet cGMP and DSCSA compliance, maintain authorized wholesaler relationships, and carry substantial commercial general liability and professional liability insurance.